Drug Safety-related Labeling Changes (SrLC)

Get Email Alerts | Guide

Drug Safety-related Labeling Changes (SrLC) Database

ANDA	Abbreviated New Drug Application
BLA	Biologics License Application
CDER	Center for Drug Evaluation and Research
MG	Medication Guide
NDA	New Drug Application
PCI	Patient Counseling Information
PI	Patient Information
PLR	Physician Labeling Rule
PLLR	Pregnancy and Lactation Labeling Rule
Italics	For the most part, italics indicate an FDA comment such as: Additions and/or revisions underlined These italics usually appear at the beginning of the section. In some cases, italics may be an inherent part of the label, and will most often appear in the body of the section.
Underlines	Any text that is underlined indicates text that has been added or revised. There are exceptions where underlining occurs in a section subtitle or heading. This is the case when there is just one word underlined in the body of the text.

Sections

BW	Box Warning
WP	Warnings and Precautions all in one section (PLR-format) Warnings as one section (pre-PLR format) Precautions as one section (pre-PLR format)
AR	Adverse Reactions (in pre-PLR format, this may be a subheading under precautions).
DI	Drug Interactions (in pre-PLR format, this may be a subheading under precautions).
USP	Use in Specific Populations (Inclusive on one or more of the following: Pregnancy; Lactation (PLLR- format); Nursing Mothers (pre-PLLR format); Females and Males of Reproductive Potential (PLLR format only); Pediatric Use, Geriatric Use, Renal Impairment, Hepatic Impairment, Sex, Race (these last six may be a subheading of precautions if label in pre-PLLR format.
PCI/PI/MG	Patient Counseling Information (PLR format only) - summarizes the information that a health care provider should convey to a patient (or caregiver when applicable) when a counseling discussion is taking place (e.g., a physician prescribing a drug during an office visit, a nurse providing discharge instructions at a hospital, or a pharmacist conveying information at a pharmacy). Patient Information - FDA approved patient labeling. Medication Guide - paper handouts that come with many prescription medicines. The guides address issues that are specific to particular drugs and drug classes, and they contain FDA-approved information that can help patients avoid serious adverse events.

Only NDAs and CDER regulated BLAs are included in this database. ANDAs are not included.

Applications that remain active, even if the product has been discontinued, undergo safety-related labeling changes.

FYARRO (NDA-213312)

(SIROLIMUS)

Safety-related Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER)

Download Data

Expand all

09/02/2026 (SUPPL-14)

Approved Drug Label (PDF)

7 Drug Interactions

7.1 Effects of Other Drugs on FYARRO

Additions and/or revisions underlined:

CYP3A Inhibitors and P-gp Inhibitors

Avoid concomitant use of FYARRO with strong CYP3A inhibitors and P-gp inhibitors, including grapefruit or grapefruit juice.

Reduce the dosage of FYARRO when used concomitantly with a moderate or weak CYP3A inhibitor

[see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].

Sirolimus is a CYP3A and P-gp substrate [see Clinical Pharmacology (12.3)]. Concomitant use with a CYP3A and P-gp inhibitor may increase sirolimus exposure [see Clinical Pharmacology (12.3)], which may increase the risk of FYARRO-associated adverse reactions.

Strong CYP3A Inducers and P-gp Inducers

Avoid concomitant use of FYARRO with strong CYP3A inducers and P-gp inducers.

Sirolimus is a CYP3A and P-gp substrate [see Clinical Pharmacology (12.3)]. Concomitant use with a CYP3A and/or P-gp inducer may decrease sirolimus exposure [see Clinical Pharmacology (12.3)], which may decrease the effectiveness of FYARRO.

8 Use in Specific Populations

8.6 Hepatic Impairment

Additions and/or revisions underlined:

Avoid use in patients with severe hepatic impairment.

Reduce FYARRO dosage in patients with mild or moderate hepatic impairment [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].